Amgen's trebananib down, not out in ovarian cancer
This article was originally published in Scrip
Executive Summary
Trebananib did not significantly improve overall survival for women with recurrent ovarian cancer, a secondary endpoint of the TRINOVA-1 trial, but Amgen has two more Phase III opportunities to show a meaningful improvement for patients with the difficult cancer.
You may also be interested in...
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.